Peringkat Kapitalisasi Pasar – Kesehatan
Kapitalisasi Pasar per Perusahaan – Sektor Kesehatan (USD) Jan 2000 - Sep 2026
Ringkasan
Pada Sep 2026, Eli Lilly memimpin dengan US$1,02 T, di atas Johnson & Johnson (US$663,28 M).
Eli Lilly sendiri menyumbang 22,7% dari total Sep 2026.
Sejak Sep 2016, Eli Lilly tumbuh paling cepat, naik 1.574,7%.
Full Rankings
Complete dataset - Sep 2026
| Peringkat | Perusahaan | Nilai | Bulanan | Pangsa % | Δ Peringkat |
|---|---|---|---|---|---|
| 1 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">LLY</text></svg>) Eli LillyLLY | US$1 T | -0,6% | 22,7% | — |
| 2 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">JNJ</text></svg>) Johnson & JohnsonJNJ | US$663,3 M | +3,5% | 14,7% | — |
| 3 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">ABBV</text></svg>) AbbVieABBV | US$453,2 M | 0,0% | 10,1% | — |
| 4 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">MRK</text></svg>) MerckMRK | US$370,9 M | +1,7% | 8,2% | — |
| 5 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">UNH</text></svg>) UnitedHealth GroupUNH | US$356,5 M | +2,0% | 7,9% | — |
| 6 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">NVS</text></svg>) NovartisNVS | US$304,1 M | +5,2% | 6,7% | — |
| 7 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">AZN</text></svg>) AstraZenecaAZN | US$252,3 M | +0,4% | 5,6% | — |
| 8 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">TMO</text></svg>) Thermo Fisher ScientificTMO | US$226,9 M | -0,5% | 5,0% | — |
| 9 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">NVO</text></svg>) Novo NordiskNVO | US$206 M | +2,8% | 4,6% | — |
| 10 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">PFE</text></svg>) PfizerPFE | US$162,2 M | 0,0% | 3,6% | — |
| 11 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">DHR</text></svg>) DanaherDHR | US$146 M | -2,8% | 3,2% | — |
| 12 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">BMY</text></svg>) Bristol-Myers SquibbBMY | US$136,5 M | 0,0% | 3,0% | — |
| 13 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">SNY</text></svg>) SanofiSNY | US$106 M | -0,3% | 2,4% | — |
| 14 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">GSK</text></svg>) GSKGSK | US$99,9 M | -0,7% | 2,2% | — |
Sumber Data & Lisensi
Dilisensikan di bawah Yahoo Terms of Service.
Data diambil dari sumber asli dan diformat oleh Data Race.
Dataset Terkait
Ekonomi
Peringkat Kapitalisasi Pasar
Kapitalisasi Pasar per Perusahaan
Jan 2000-Sep 2026 130 Perusahaan
Ekonomi
Peringkat Kapitalisasi Pasar – Teknologi
Kapitalisasi Pasar per Perusahaan – Sektor Teknologi
Jan 2000-Sep 2026 16 Perusahaan
Ekonomi
Peringkat Kapitalisasi Pasar – Semikonduktor
Kapitalisasi Pasar per Perusahaan – Sektor Semikonduktor
Jan 2000-Sep 2026 15 Perusahaan
Ekonomi
Peringkat Kapitalisasi Pasar – Keuangan
Kapitalisasi Pasar per Perusahaan – Sektor Keuangan
Jan 2000-Sep 2026 15 Perusahaan
Ekonomi
Peringkat Kapitalisasi Pasar – Energi
Kapitalisasi Pasar per Perusahaan – Sektor Energi
Jan 2000-Sep 2026 14 Perusahaan
Ekonomi
Peringkat Kapitalisasi Pasar – Konsumen
Kapitalisasi Pasar per Perusahaan – Sektor Konsumen
Jan 2000-Sep 2026 14 Perusahaan